CN Patent

CN111032042A — 哌啶基-吲哚衍生物的新用途

Assigned to Novartis AG · Expires 2020-04-17 · 6y expired

What this patent protects

本发明涉及某些哌啶基‑吲哚衍生物在治疗患有肾疾病或障碍的患者中的新用途，并且特别是用于在治疗患有C3G(C3肾小球病)和IgAN(IgA肾病)的患者中的新用途。

USPTO Abstract

本发明涉及某些哌啶基‑吲哚衍生物在治疗患有肾疾病或障碍的患者中的新用途，并且特别是用于在治疗患有C3G(C3肾小球病)和IgAN(IgA肾病)的患者中的新用途。

Drugs covered by this patent

iptacopan-hydrochloride (IPTACOPAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN111032042A
Jurisdiction: CN
Classification: —
Expires: 2020-04-17
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.